Here is where we will share the most updated industry news with you.
- A new study from MD Anderson states that while Intensity-Modulated Proton Therapy(IMPT) was on average more costly than Intensity-Modulated Radiation Therapy(IMRT), primarily due to higher equipment costs, a subset of IMRT patients had similar costs to IMPT patients, due to a greater use of supportive care resources. Click here to learn more.
- Proton therapy has been proven by many prospective and retrospective studies as a promising treatment in the management of prostate cancer. On April 12, 2021, the Particle Therapy Co-Operative Group (PTCOG) published a Consensus Statement on #protontherapy for prostate cancer to help people better understand current proton therapy indications, advantages, disadvantages, and cost effectiveness. Click here to learn more.
- Surgery is the standard treatment for ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. A new study suggests that Proton Therapy Treatment is a promising alternative for patients with (GGO)-type lung cancer when surgical resection is not feasible. http://medipolis-ptrc.org/cms/wp-content/uploads/2020/10/202010_Lung-ca-ncer_clinical-outcomes-of-proton-beam-therapy-for-ground-glass-op_62376.pdf
- Proton therapy has been proven as an effective tool to improve oncologic outcomes and reduce toxicities from treatment of the majority of thoracic malignancies. Learn more at: https://www.tandfonline.com/doi/full/10.1080/14737140.2021.1844567
- The newest study from Penn Medicine reveals that treating lung cancer patients with proton therapy for may help reduce the risk of radiation-induced heart diseases. https://www.pennmedicine.org/news/news-releases/2020/october/proton-therapy-for-lung-cancer-may-help-reduce-risk-of-heart-diseases
- A new study from Japan finds that proton therapy can control renal cell carcinoma while maintaining patient’s renal function with high probability, and could be an alternative curative therapy especially for inoperable patients. http://iv.iiarjournals.org/content/34/5/2883.short
- The use of proton therapy in adolescents and young adults (AYAs) is becoming increasingly popular. A recent study finds that PT is an effective treatment for brain/skull base tumors in the AYA population with a reasonable late toxicity profile. https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.28664
- Proton therapy is always considered a powerful tool for treatment of pediatric cancer patients because their developing bodies are more sensitive to the side effects of traditional radiation therapy. There have been many research papers published related to the treatment of children with PBT in recent years. Yet, there is little research on how parents of these pediatric patients perceive their child’s PBT and the information sources they encounter.Check the link to read the article that offers a perspective of how parents inform themselves when their child is treated with this advanced mode of radiotherapy.
- Proton Beam Therapy is well known to have the advantage of reducing the irradiated volume and dose to surrounding normal tissue, in patients with lung cancer, compared with SBRT. A nationwide retrospective study from Japan, published in International Journal of Radiation Oncology, proved that proton beam therapy yielded acceptable survival rates, with a low rate of toxicities for Stage 1 Non-Small Cell Lung Cancer. https://www.redjournal.org/article/S0360-3016(19)33837-4/fulltext
- A new study published by the American Cancer Society finds that high tech proton therapy achieves remarkable local control for patients with nasal cavity and paranasal sinus cancers, as well as having the potential to improve the therapeutic ratio in these malignancies.
- The Annual Report to the Nation on the Status of Cancer published by the American Cancer Society states that “Although overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances.”
Subscribe ProTom for more information.